Phase 1/2 study of lumiliximab combined with fludarabine, cyclophosphamide, and rituximab in patients with relapsed or refractory chronic lymphocytic leukemia

Preclinical data demonstrate enhanced antitumor effect when lumiliximab, an anti-CD23 monoclonal antibody, is combined with fludarabine or rituximab. Clinical data from a phase 1 trial with lumiliximab demonstrated an acceptable toxicity profile in patients with relapsed or refractory chronic lympho...

Volledige beschrijving

Bewaard in:
Bibliografische gegevens
Hoofdauteurs: Byrd, John C., Kipps, Thomas J., Flinn, Ian W., Castro, Januaro, Lin, Thomas S., Wierda, William, Heerema, Nyla, Woodworth, James, Hughes, Steve, Tangri, Shabnam, Harris, Sarah, Wynne, Dee, Molina, Arturo, Leigh, Bryan, O'Brien, Susan
Formaat: Artigo
Taal:Inglês
Gepubliceerd in: American Society of Hematology 2010
Onderwerpen:
Clinical Trials and Observations
Online toegang:https://ncbi.nlm.nih.gov/pmc/articles/PMC2810983/
https://ncbi.nlm.nih.gov/pubmed/19843887
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2009-08-237727
Tags: Voeg label toe
Geen labels, Wees de eerste die dit record labelt!

Gelijkaardige items